Abstract |
Vulvo-vaginal candidiasis (VVC) is a common infection among women. 5% of women with acute infection experience recurrent vulvo-vaginal candidiasis (RVVC). There is currently no optimal or recommended regime for RVVC. Although antifungal agents, such as imidazoles, have been successfully used as a first-line treatment for acute VVC, its effectiveness is limited in RVVC. This could be due to patient factors, drug application (such as leakage) or dosing factors. A sustained-release (SR) bioadhesive vaginal cream (2% butoconazole nitrate) has incorporated VagiSite technology, a topical drug delivery system that allows SR of the drug. We describe its efficacy and the successful use of a butoconazole-SR formulation in the treatment of two cases of RVVC.
|
Authors | Ling Zhi Heng, Yujia Chen, Thiam Chye Tan |
Journal | Singapore medical journal
(Singapore Med J)
Vol. 53
Issue 12
Pg. e269-71
(Dec 2012)
ISSN: 0037-5675 [Print] India |
PMID | 23268172
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antifungal Agents
- Imidazoles
- butoconazole
|
Topics |
- Adult
- Antifungal Agents
(administration & dosage)
- Candidiasis, Vulvovaginal
(drug therapy)
- Female
- Humans
- Imidazoles
(administration & dosage)
- Middle Aged
- Pessaries
- Recurrence
|